Cidara Therapeutics, Inc. CDTX
Set alert
221.38 USD 0.00 0.00%
As of Jan 8, 9:30 AM ET
221.38 Day range 221.38
94.50 52-week range 221.42
- YTD
- +0.22%
- 1 year
- +725.74%
- Open
- 221.38
- Prev close
- 221.38
- Mkt cap
- 5.61B
- Vol
- 2.69M
- Avg vol
- 919.35K
- EPS
- -11.78
- P/E
- -46.61
- Div yield
- 0.00%
More statistics
- Low
- 221.38
- High
- 221.38
- Beta
- 1.53
- Inst. own
- 103.89%
- Dividend
- 0.00
2Y chart
Events in this range
- Apr 24, 2024Split: 1 for 20
- Aug 13, 2024Earnings: -19.99; estimate -3.94; surprise -407.36%
- Nov 7, 2024Earnings: -2.38; estimate -5.22; surprise 54.41%
- Mar 6, 2025Earnings: -5.38; estimate -5.28; surprise -1.89%
- May 8, 2025Earnings: -1.66; estimate -5.45; surprise 69.54%
- Aug 7, 2025Earnings: -1.65; estimate -1.87; surprise 11.76%
- Oct 21, 2025Rating: HC Wainwright & Co. · Buy → Buy
- Nov 6, 2025Earnings: -3.1; estimate -1.34; surprise -131.34%
- Nov 7, 2025Rating: Needham · Buy → Buy
- Nov 7, 2025Rating: RBC Capital · Outperform → Outperform
- Nov 14, 2025Downgrade: Needham · Buy → Hold
- Nov 14, 2025Downgrade: HC Wainwright & Co. · Buy → Neutral
- Nov 18, 2025Downgrade: Guggenheim · Buy → Neutral
Signals (87)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Dec 4, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 14, 2025 | 11 months ago |
| RSI: Overbought | Nov 14, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 16, 2025 | 1 year ago |
| RSI: Overbought | Oct 9, 2025 | 1 year ago |
| RSI: Overbought | Sep 24, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 18, 2025 | 1 year ago |
| RSI: Overbought | Aug 15, 2025 | 1 year ago |
| RSI: Overbought | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 16, 2025 | 1 year ago |
| RSI: Overbought | Jul 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 23, 2025 | 1 year ago |
| RSI: Overbought | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 6, 2025 | 1 year ago |
| MACD: Sell Signal | May 29, 2025 | 1 year ago |
| MACD: Buy Signal | May 16, 2025 | 1 year ago |
| RSI: Overbought | May 16, 2025 | 1 year ago |
| SMA: Bullish | May 15, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | May 1, 2025 | 1 year ago |
| SMA: Bearish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| SMA: Bullish | Apr 8, 2025 | 1 year ago |
| SMA: Bearish | Apr 4, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 28, 2025 | 1 year ago |
| SMA: Bearish | Mar 26, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 25, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 14, 2025 | 1 year ago |
| SMA: Bullish | Mar 12, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 10, 2025 | 1 year ago |
| SMA: Bullish | Feb 27, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| SMA: Bearish | Feb 21, 2025 | 1 year ago |
| SMA: Bullish | Feb 11, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 6, 2025 | 1 year ago |
| SMA: Bearish | Jan 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 8, 2025 | 1 year ago |
| RSI: Overbought | Jan 6, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 31, 2024 | 1 year ago |
| RSI: Overbought | Dec 31, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 18, 2024 | 1 year ago |
| RSI: Overbought | Dec 6, 2024 | 1 year ago |
| RSI: Overbought | Nov 13, 2024 | 1 year ago |
| SMA: Bullish | Oct 31, 2024 | 2 years ago |
| SMA: Bearish | Oct 30, 2024 | 2 years ago |
| SMA: Bullish | Oct 29, 2024 | 2 years ago |
| RSI: Overbought | Oct 29, 2024 | 2 years ago |
| SMA: Bullish | Oct 25, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 16, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 15, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 7, 2024 | 2 years ago |
| SMA: Bearish | Aug 30, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 30, 2024 | 2 years ago |
| SMA: Bullish | Aug 14, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 14, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Aug 2, 2024 | 2 years ago |
| SMA: Bullish | Jul 26, 2024 | 2 years ago |
| SMA: Bearish | Jul 19, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 15, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 9, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 5, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 20, 2024 | 2 years ago |
| SMA: Bearish | Jun 14, 2024 | 2 years ago |
| SMA: Bullish | Jun 12, 2024 | 2 years ago |
| MACD: Buy Signal | May 22, 2024 | 2 years ago |
| MACD: Sell Signal | May 20, 2024 | 2 years ago |
| MACD: Buy Signal | May 7, 2024 | 2 years ago |
| RSI: Oversold | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 16, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 11, 2024 | 2 years ago |
| RSI: Overbought | Mar 28, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 19, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 11, 2024 | 2 years ago |
Key statistics
- Market cap
- 5.61B
- Enterprise value
- 5.32B
- Trailing P/E
- -46.61
- PEG ratio
- -1.58
- Price / sales
- 0.00
- Price / book
- 8.15
- Beta
- 1.53
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -23.59%
Analyst view
Price target (mean) —
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.33.
Financials — quick view
CDTX Revenue — quarterly 0
CDTX Net income — quarterly -83.23M
CDTX EPS — quarterly -3.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2025 | Sep 30, 2025 | -1.34 | -3.10 | -1.76 | -131.34% |
| Aug 7, 2025 | Jun 30, 2025 | -1.87 | -1.65 | +0.22 | +11.76% |
| May 8, 2025 | Mar 31, 2025 | -5.45 | -1.66 | +3.79 | +69.54% |
| Mar 6, 2025 | Dec 31, 2024 | -5.28 | -5.38 | -0.10 | -1.89% |
| Nov 7, 2024 | Sep 30, 2024 | -5.22 | -2.38 | +2.84 | +54.41% |
| Aug 13, 2024 | Jun 30, 2024 | -3.94 | -19.99 | -16.05 | -407.36% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2025 | Guggenheim | down | Buy | Neutral |
| Nov 14, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 14, 2025 | Needham | down | Buy | Hold |
| Nov 7, 2025 | RBC Capital | main | Outperform | Outperform |
| Nov 7, 2025 | Needham | main | Buy | Buy |
| Oct 21, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 38
- Website
- msd.platform-apps.io
News
- Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?
- Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
- Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
- 3,187 Shares in Cidara Therapeutics, Inc. $CDTX Bought by ANB Bank
- Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Hold” from Analysts
- Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
- Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Hold” from Brokerages
- 3 Potential Mid-Cap Biotech Buyout Targets In 2026
- Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX
- Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
Your note
Sign in to keep a note on CDTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAVARPANAH NICOLE NEGAR | Officer | Stock Gift | Dec 28, 2025 | 20,886 |
| KARBE FRANK L | Chief Financial Officer | Stock Award(Grant) | Feb 23, 2025 | 57,500 |
| MINEO CHRYSA | Director | Purchase | Jun 2, 2025 | 3,320 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 25, 2025 | 0 |
| SANDISON TAYLOR | Officer | Sale | Sep 10, 2024 | 23,067 |
| SHAH PREETAM | Chief Financial Officer | Stock Award(Grant) | Mar 14, 2024 | 335,960 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, LLC | 13.27% | 3,365,523 | 0 | Jun 29, 2025 |
| Bain Capital Life Sciences Investors, LLC | 9.86% | 2,500,680 | 0 | Jun 29, 2025 |
| Point72 Asset Management, L.P. | 6.03% | 1,527,930 | 0 | Jun 29, 2025 |
| Vivo Capital, LLC | 5.17% | 1,311,425 | 0 | Jun 29, 2025 |
| COMMODORE CAPITAL LP | 4.63% | 1,175,000 | 0 | Jun 29, 2025 |
| BlackRock Inc | 4.37% | 1,107,668 | 0 | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.34% | 592,283 | 0 | Jul 30, 2025 |
| iShares Russell 2000 ETF | 1.59% | 404,282 | 0 | Aug 30, 2025 |
| abrdn Healthcare Investors | 0.71% | 179,902 | 0 | Aug 30, 2025 |
| Fidelity Small Cap Index | 0.66% | 168,540 | 0 | Jun 29, 2025 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.63% | 159,673 | 0 | Jul 30, 2025 |
| iShares Russell 2000 Value ETF | 0.58% | 147,778 | 0 | Aug 30, 2025 |